Plasma lncRNA FEZF1-AS1 as a potential biomarker for diagnosis of non-small-cell lung carcinoma

Huang, Yajie; Liu, Guangjie; Ma, Handie; Tian, Yanpeng; Huang, Chien-Hung; Liu, Fang; Jia, Yuxuan; Jiang, Da

doi:10.1097/md.0000000000021019

Cited by 4 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the occurrence of early metastasis in lung cancer patients is of great importance for the selection of appropriate treatment plans. Currently, noninvasive tests such as long-non-coding RNA (Lnc RNA), neuron-specific enolase (NSE), circulating tumor DNA (ct DNA) and microRNAs have good diagnostic value for early diagnosis and cancer staging of lung cancer (11)(12)(13)(14), however, there are few reports on the diagnosis of metastasis in non-small cell lung cancer. Liquid biopsy and tissue biopsy are the gold standard for cancer diagnosis, however, due to the limitations of their operation such as invasiveness, complexity, inability to monitor longitudinally and continuous monitoring, and clinical variability of patients (15,16), monitoring cannot be routinely performed in lung cancer patients.…”

Section: Introductionmentioning

confidence: 99%

Immune cell-lipoprotein imbalance as a marker for early diagnosis of non-small cell lung cancer metastasis

Zhang

Wang²,

Wu³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

The underlying molecular mechanisms and evolutionary patterns of lung cancer metastasis remain unclear, resulting in a lack of effective indicators for early diagnosis of metastasis. We retrospectively analyzed 117 patients with primary non-small cell lung cancer (NSCLC) admitted to Tongji Hospital of Tongji University in 2021, of which 93 patients with tumor metastasis were set as the metastasis group. 24 patients without metastasis were set as the non-metastasis group. The differences of each index in the two groups of patients and the expression levels in different TNM stages were compared. This study intends to evaluate the diagnostic value and net clinical benefit of common blood-related indicators Neutrophil/lymphocyte (NLR), lymphocyte/monocyte (LMR), High density lipoprotein/neutrophil (HNR), High density lipoprotein/monocyte (HMR) and combined assays in NSCLC metastasis for the early diagnosis of patients with NSCLC metastasis. It was found that the level of NLR was higher in metastatic NSCLC than non-metastatic, but the level of LMR, HNR and HMR was lower. The levels of NLR, LMR, HNR and HMR in patients with different TNM stages showed that NLR levels increased with TNM stage, while LMR, HNR and HMR levels decreased. The threshold probability range of the 4 combined tests was greater and the overall clinical benefit rate was higher compared to the individual tests. Our findings suggest that NLR, LMR, HNR and HMR have better diagnostic value for NSCLC metastasis. This study provides a clinical basis for investigating the mechanisms by which immune cells and lipid metabolism-related proteins remodel the microenvironment prior to NSCLC metastasis.

show abstract

Section: Introductionmentioning

confidence: 99%

Immune cell-lipoprotein imbalance as a marker for early diagnosis of non-small cell lung cancer metastasis

Zhang

Wang²,

Wu³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Recently, studies have revealed that lncRNAs play critical roles in the carcinogenesis and cancer progression of a variety of cancers, including GC ( Yu and Rong, 2018 ; Ghafouri-Fard and Taheri, 2020 ). For example, FEZF1-AS1, a top overexpressed lncRNA in colorectal cancer, has been found to be involved in the initiation and progression of various cancers including colorectal carcinoma ( Chen et al, 2016 ; Bian et al, 2018 ), non-small cell lung cancer ( Huang et al, 2020 ) and gastric cancer ( Wu et al, 2017 ). However, the molecular mechanism of FEZF1-AS1 plays in GC, particularly in chemoresistance of GC cells has not yet been clarified.…”

Section: Discussionmentioning

confidence: 99%

“…As described in previously studies ( Bian et al, 2018 ), lncRNA FEZF1-AS1 was upregulated in primary colorectal carcinoma (CRC), non-small cell lung cancer (NSCLC) as well as GC tissues and cells, and the overexpression of ncRNA FEZF1-AS1 was correlated with poor prognosis. Dysregulation of lncRNA FEZF1-AS1 promoted the proliferation and migration of CRC ( Bian et al, 2018 ), NSCLC ( Huang et al, 2020 ), and GC cells ( Hui et al, 2020 ). Furthermore, knock down of lncRNA FEZF1-AS1 significantly suppressed the proliferation and invasion of tumor cells ( Chen et al, 2016 ; Bian et al, 2018 ).…”

Section: Introductionmentioning

confidence: 99%

LncRNA FEZF1-AS1 Promotes Multi-Drug Resistance of Gastric Cancer Cells via Upregulating ATG5

Gui

Zhao

Sun

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) play important roles in human cancers including gastric cancer (GC). Dysregulation of lncRNAs is involved in a variety of pathological activities associated with gastric cancer progression and chemo-resistance. However, the role and molecular mechanisms of FEZF1-AS1 in chemoresistance of GC remain unknown. In this study, we aimed to determine the role of FEZF1-AS1 in chemoresistance of GC. The level of FEZF1-AS1 in GC tissues and GC cell lines was assessed by qRT-PCR. Our results showed that the expression of FEZF1-AS1 was higher in gastric cancer tissues than in adjacent normal tissues. Multivariate analysis identified that high level of FEZF1-AS1 is an independent predictor for poor overall survival. Increased FEZF1-AS1 expression promoted gastric cancer cell proliferation in vitro. Additionally, FEZF1-AS1 was upregulated in chemo-resistant GC tissues. The regulatory effect of FEZF1-AS1 on multi-drug resistance (MDR) in GC cells and the underlying mechanism was investigated. It was found that increased FEZF1-AS1 expression promoted chemo-resistance of GC cells. Molecular interactions were determined by RNA immunoprecipitation (RIP) and the results showed that FEZF1-AS1 regulated chemo-resistance of GC cells through modulating autophagy by directly targeting ATG5. The proliferation and autophagy of GC cells promoted by overexpression of LncFEZF1-AS1 was suppressed when ATG5 was knocked down. Moreover, knockdown of FEZF1-AS1 inhibited tumor growth and increased 5-FU sensitivity in GC cells in vivo. Taken together, this study revealed that the FEZF1-AS1/ATG5 axis regulates MDR of GC cells via modulating autophagy.

show abstract

“…Compared with those studies of circulating lncRNAs in diagnosing NSCLC (29)(30)(31)(32), our study is unique for the following reasons: Firstly, we selected 31 lung cancer related lncRNAs based on the previous studies and screened the expression of these lncRNAs in the plasma, which make it easier to obtain effective diagnostic markers for lung cancer. Secondly, we included not only healthy controls but also benign lung diseases in the control group.…”

Section: Discussionmentioning

confidence: 99%

Circulating Long Noncoding RNAs Act as Diagnostic Biomarkers in Non-Small Cell Lung Cancer

et al. 2020

View full text Add to dashboard Cite

Identification of novel effective early diagnostic biomarkers may provide alternative strategies to reduce the mortality for non-small cell lung cancer (NSCLC) patients. Circulating long non-coding RNAs (lncRNAs) have emerged as a new class of promising cancer biomarkers. Our study aimed to identify circulating lncRNAs for diagnosing NSCLC. A total 528 plasma samples were continuously collected and allocated to four progressive phases: discovery, training, verification, and expansion phases. The expression of candidate lung cancer related lncRNAs were detected using quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR). We identified a 4-lncRNA panel (RMRP, NEAT1, TUG1, and MALAT1) that provided a high diagnostic value in NSCLC (AUC = 0.86 and 0.89 for training and verification phase, respectively). Subgroup analyses showed that the 4-lncRNA panel had a sensitivity of 78.95% [95% confidence interval (CI) = 62.22%–89.86%] in stage I-II patients and 75.00% (95% CI = 52.95%–89.40%) in patients with small tumor size (≤3cm). Notably, the sensitivity of 4-lncRNA panel was significantly higher than that of routine protein panels in adenocarcinoma (CEA, CA125, and CYFRA21-1, 86.30% vs. 73.96%). Adding 4-lncRNA to protein markers significantly improved the diagnostic capacity in both adenocarcinoma (AUC=0.85, 95% CI = 0.78–0.91) and squamous cell carcinoma (AUC=0.93, 95% CI = 0.86–0.97). In conclusion, we identified a plasma 4-lncRNA panel that has considerable clinical value in diagnosing NSCLC. The 4-lncRNA panel could improve the diagnostic values of routine tumor protein markers in diagnosing NSCLC. Circulating lncRNAs could be used as promising candidates for NSCLC diagnosis.

show abstract

Plasma lncRNA FEZF1-AS1 as a potential biomarker for diagnosis of non-small-cell lung carcinoma

Cited by 4 publications

References 18 publications

Immune cell-lipoprotein imbalance as a marker for early diagnosis of non-small cell lung cancer metastasis

Immune cell-lipoprotein imbalance as a marker for early diagnosis of non-small cell lung cancer metastasis

LncRNA FEZF1-AS1 Promotes Multi-Drug Resistance of Gastric Cancer Cells via Upregulating ATG5

Circulating Long Noncoding RNAs Act as Diagnostic Biomarkers in Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About